New research reveals that intermittent fasting can significantly enhance the effectiveness of oestrogen-blocking breast ...

In premenopausal women with non-metastatic breast cancer, use of tamoxifen may nearly double the risk of endometrial cancer, researchers report.

As of Thursday, December 11, Atossa Therapeutics, Inc.’s ATOS share price has surged by 9.41%, which has investors ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

Study marks first improvement in adjuvant endocrine therapy for early breast cancer in 20 ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...

The investigational, oral selective estrogen receptor degrader (SERD) giredestrant  given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with ...

Adjuvant giredestrant significantly improved invasive DFS vs. standard-of-care endocrine therapy in patients with early-stage ...

Atossa Therapeutics, Inc. ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced ...